{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["62"],"submitter":["Zhong GH"],"pubmed_abstract":["Background
Cecolin9, a second-generation 9-valent HPV vaccine derived from the WHO-prequalified Cecolin, has received marketing authorisation in China in May 2025. The non-inferiority of type-specific immune responses between Cecolin9 and Gardasil9 has been previously established at month 7 in Chinese women aged 18-26 years (NCT04782895). This study aimed to compare the plateau antibody levels between the two vaccines three years post the first dose.Methods
This was a prospective extension study of a randomised, single-blind trial conducted in China (ClinicalTrials.gov, NCT06197802). All the participants included in the base study were invited to participate in this extension. Blood samples were collected at year 3 (median follow-up time of 34 months) for neutralising antib"],"journal":["The Lancet regional health. Western Pacific"],"pagination":["101671"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12408396"],"repository":["biostudies-literature"],"pubmed_title":["Immunogenicity comparison of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial."],"pmcid":["PMC12408396"],"pubmed_authors":["Chen Q","Zhu KX","Zhang J","Zhang ML","Nie LL","Chen L","Zhang L","Liu S","Xia NS","Li K","Li JX","Nie C","Xu JB","Bi ZF","Huang WJ","Quan JL","Su YY","Chu K","Qiu LX","Huang SJ","Wu T","Zhang QF","Zhong GH","Pan HX"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity comparison of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial.","description":"Background
Cecolin9, a second-generation 9-valent HPV vaccine derived from the WHO-prequalified Cecolin, has received marketing authorisation in China in May 2025. The non-inferiority of type-specific immune responses between Cecolin9 and Gardasil9 has been previously established at month 7 in Chinese women aged 18-26 years (NCT04782895). This study aimed to compare the plateau antibody levels between the two vaccines three years post the first dose.Methods
This was a prospective extension study of a randomised, single-blind trial conducted in China (ClinicalTrials.gov, NCT06197802). All the participants included in the base study were invited to participate in this extension. Blood samples were collected at year 3 (median follow-up time of 34 months) for neutralising antib","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T07:00:47.766Z","creation":"2026-05-29T03:05:53.994Z"},"accession":"S-EPMC12408396","cross_references":{"pubmed":["40919385"],"doi":["10.1016/j.lanwpc.2025.101671"]}}